Home » Stocks » Genmab A/S

Genmab A/S (GMAB)

Stock Price: $35.87 USD -0.18 (-0.50%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $36.88 +1.01 (2.82%) Aug 11, 5:43 PM

Stock Price Chart

Key Info

Market Cap 23.39B
Revenue (ttm) 845.42M
Net Income (ttm) 341.26M
Shares Out 651.83M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 31.75
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $35.87
Previous Close $36.05
Change ($) -0.18
Change (%) -0.50%
Day's Open 36.71
Day's Range 35.61 - 36.86
Day's Volume 634,022
52-Week Range 24.13 - 36.86

More Stats

Market Cap 23.39B
Enterprise Value 21.69B
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 651.83M
Float 642.65M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share 0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.82%
Payout Ratio n/a
Shares Short 889,516
Short Ratio 0.72
Short % of Float n/a
Beta 0.50
PE Ratio n/a
Forward PE 31.75
P/FCF Ratio 122.18
PS Ratio 27.67
PB Ratio 10.37
Revenue 845.42M
Operating Income 415.62M
Net Income 341.26M
Free Cash Flow 191.43M
Net Cash 1.70B
Net Cash / Share 2.61
Gross Margin 100.00%
Operating Margin 49.16%
Profit Margin 40.40%
FCF Margin 22.64%
ROA 14.22%
ROE 20.98%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (22)

Buy 12
Overweight 1
Hold 6
Underweight 1
Sell 2

Analyst Consensus: Overweight

Price Target

$33.43*
(-6.80% downside)
Low
20.7
Current: $35.87
High
40.0
Target: 33.43
*Average 12-month USD price target from 20 stock analysts.

Financial Performance

Financial numbers in millions DKK.

Financial Overview

Year201920182017
Revenue5,3663,0252,365
Revenue Growth77.39%27.91%-
Gross Profit5,3663,0252,365
Operating Income2,6381,3801,344
Net Income2,1661,4721,104
Shares Outstanding64.3064.30-
Earnings Per Share3.402.371.78
EPS Growth43.4%33.54%-
Operating Cash Flow1,3261,0151,589
Capital Expenditures-111-478-89.00
Free Cash Flow1,2155371,500
Cash & Equivalents10,9716,1065,423
Total Debt181--
Net Cash / Debt10,7906,1065,423
Assets15,1448,4616,603
Liabilities1,096447331
Book Value14,0488,0146,272
Numbers in millions DKK, except per-share numbers.

Company Profile

Company Details

Full Name Genmab A/S
Country Denmark
Employees 579
CEO Jan G. J. van de Winkel

Stock Information

Ticker Symbol GMAB
Stock Exchange NASDAQ
Unique Identifier NASDAQ: GMAB

Description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.